Akebia Therapeutics, Inc. (FRA:AX9)

Market Cap	346.77M
Revenue (ttm)	191.83M
Net Income (ttm)	-13.56M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	13.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	113
Open	1.252
Previous Close	1.250
Day's Range	1.252 - 1.252
52-Week Range	1.250 - 3.538
Beta	n/a
RSI	39.10
Earnings Date	Mar 12, 2026

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 181
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AX9

Financial Performance

In 2024, Akebia Therapeutics's revenue was $160.18 million, a decrease of -17.70% compared to the previous year's $194.62 million. Losses were -$69.41 million, 33.7% more than in 2023.

Financial numbers in USD